177 related articles for article (PubMed ID: 9517872)
1. Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy.
Napoli PA; Dorrucci M; Serraino D; Pezzotti P; Franceschi S; Vella S; Rezza G
Eur J Epidemiol; 1998 Jan; 14(1):41-7. PubMed ID: 9517872
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
[TBL] [Abstract][Full Text] [Related]
4. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
5. Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis.
Abgrall S; Matheron S; Le Moing V; Dupont C; Costagliola D;
J Acquir Immune Defic Syndr; 2001 Feb; 26(2):151-8. PubMed ID: 11242182
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.
Yangco BG; Von Bargen JC; Moorman AC; Holmberg SD
Ann Intern Med; 2000 Feb; 132(3):201-5. PubMed ID: 10651600
[TBL] [Abstract][Full Text] [Related]
8. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease.
Eldred LJ; Wu AW; Chaisson RE; Moore RD
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):117-25. PubMed ID: 9637576
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
10. Clinic HIV-focused features and prevention of Pneumocystis carinii pneumonia.
Turner BJ; Markson L; Cocroft J; Cosler L; Hauck WW
J Gen Intern Med; 1998 Jan; 13(1):16-23. PubMed ID: 9462490
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l.
Koletar SL; Heald AE; Finkelstein D; Hafner R; Currier JS; McCutchan JA; Vallee M; Torriani FJ; Powderly WG; Fass RJ; Murphy RL;
AIDS; 2001 Aug; 15(12):1509-15. PubMed ID: 11504983
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
[TBL] [Abstract][Full Text] [Related]
14. Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic.
Easterbrook PJ; Yu LM; Goetghebeur E; Boag F; McLean K; Gazzard B
AIDS; 2000 Mar; 14(5):561-71. PubMed ID: 10780719
[TBL] [Abstract][Full Text] [Related]
15. Pneumocystis carinii pneumonia in the Federal Republic of Germany in the era of changing antiretroviral therapy - IDKF 13 -. German AIDS Study Group (GASG/IdKF).
Stoehr A; Arasteh K; Staszewski S; Brockmeyer N; Albrecht H; Mertenskötter T; Jablonowski H; Emminger C; Rockstroh JK; Baumgarten R; Bogner J; Loch T; Plettenberg A
Eur J Med Res; 1999 Apr; 4(4):131-4. PubMed ID: 10205287
[TBL] [Abstract][Full Text] [Related]
16. [Impact of zidovudine treatment and the pneumocystis carinii prophylaxis in natural history of patients with HIV infection].
Sáiz Hervas E; Castilla Castellano V; Miquel Plaza J; Benito Blanco AM; Martín Llorens MM; Pastor de Blas M; Izquierdo P; Muñoz Jareño MA; Sierra A; Nieto MA; Moreno Collado AM; Fraguas C
An Med Interna; 1998 Mar; 15(3):132-7. PubMed ID: 9580410
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.
Dorrucci M; Pezzotti P; Phillips AN; Alliegro MB; Rezza G
AIDS; 1997 Mar; 11(4):461-7. PubMed ID: 9084793
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review.
Costiniuk CT; Fergusson DA; Doucette S; Angel JB
PLoS One; 2011; 6(12):e28570. PubMed ID: 22194853
[TBL] [Abstract][Full Text] [Related]
20. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention.
MMWR Recomm Rep; 1995 Apr; 44(RR-4):1-11. PubMed ID: 7565543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
